Press release
Bronchopulmonary Dysplasia Pipeline Analysis 2025: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Bronchopulmonary Dysplasia Pipeline
(Albany, USA) DelveInsight's, "Bronchopulmonary Dysplasia Pipeline Insight 2025" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Bronchopulmonary Dysplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The Bronchopulmonary Dysplasia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The Bronchopulmonary Dysplasia pipeline report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Explore our latest breakthroughs in Bronchopulmonary Dysplasia Pipeline. Learn more about our emerging therapies today! @ [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Key Takeaways from the Bronchopulmonary Dysplasia Pipeline Report
* In September 2024:- EXO Biologics S.A.- Phase I Single Arm, Dose Escalating and Phase II Double Blind, Randomized, Placebo-controlled, Dose Finding Clinical Trial Assessing Safety and Efficacy of Intratracheal Administration of Allogeneic Umbilical Cord Mesenchymal Cells-derived Extracellular Vesicles in Preventing Bronchopulmonary Dysplasia in Extremely Preterm Newborns.
* DelveInsight's Bronchopulmonary Dysplasia pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Bronchopulmonary Dysplasia treatment.
* The leading Bronchopulmonary Dysplasia Companies such as MEDIPOST Co., Ltd., Airway Therapeutics, Oak Hill Bio Ltd, Meridigen Biotech, AyuVis Research, CHIESI Farmaceutici S.p.A., Velvio, Orphanix, Alveolus Bio Inc., Advent Therapeutics, Trimunocor, The Cell Factory BVBA, Windtree Therapeutics, and others.
* Promising Bronchopulmonary Dysplasia Therapies such as Sildenafil, PNEUMOSTEM, OHB-607, and others.
Stay informed about the cutting-edge advancements in Bronchopulmonary Dysplasia Treatments. Download for updates and be a part of the revolution in cancer care @ [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Emerging Bronchopulmonary Dysplasia Drugs Profile
PNEUMOSTEM: MEDIPOST Co., Ltd
PNEUMOSTEM Registered an allogeneic umbilical cord blood-derived mesenchymal stem cell product, is currently under development for the preventive treatment of Bronchopulmonary Dysplasia (BPD) in premature infants. Currently, Phase 2 clinical trial is ongoing in Korea and PNEUMOSTEM Registered has been Orphan Drug designated by US FDA and EMA. Recently, US FDA granted a Fast Track Designation for PNEUMOSTEM Registered.
AT-100: Airway Therapeutics
AT-100 is a novel recombinant human protein rhSP-D, an engineered version of an endogenous protein that reduces inflammation and infection in the body while modulating the immune response to break the cycle of injury and inflammation. Airway is focused on advancing AT-100 for the prevention of BPD in very preterm born babies and as a therapeutic for seriously ill COVID-19 patients. AT-100's anti-inflammatory and anti-infective properties also make it a potential treatment for other respiratory diseases such as influenza, respiratory syncytial virus (RSV) and inflammatory diseases outside the lung. The FDA and European Medicines Agency have granted AT-100 Orphan Drug Designation.
Learn more about Bronchopulmonary Dysplasia Drugs opportunities @ [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Bronchopulmonary Dysplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Bronchopulmonary Dysplasia Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Discover the latest advancements in Bronchopulmonary Dysplasia Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Scope of the Bronchopulmonary Dysplasia Pipeline Report
* Coverage- Global
* Bronchopulmonary Dysplasia Companies- MEDIPOST Co., Ltd., Airway Therapeutics, Oak Hill Bio Ltd, Meridigen Biotech, AyuVis Research, CHIESI Farmaceutici S.p.A., Velvio, Orphanix, Alveolus Bio Inc., Advent Therapeutics, Trimunocor, The Cell Factory BVBA, Windtree Therapeutics, and others.
* Bronchopulmonary Dysplasia Therapies- Sildenafil, PNEUMOSTEM, OHB-607, and others.
* Bronchopulmonary Dysplasia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Bronchopulmonary Dysplasia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Bronchopulmonary Dysplasia Pipeline on our website @ [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Content
* Introduction
* Executive Summary
* Bronchopulmonary Dysplasia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Bronchopulmonary Dysplasia - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* PNEUMOSTEM: MEDIPOST Co., Ltd.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* AT-100: Airway Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* AVR 48: AyuVis Research
* Drug profiles in the detailed report.....
* Inactive Products
* Bronchopulmonary Dysplasia Key Companies
* Bronchopulmonary Dysplasia Key Products
* Bronchopulmonary Dysplasia- Unmet Needs
* Bronchopulmonary Dysplasia- Market Drivers and Barriers
* Bronchopulmonary Dysplasia- Future Perspectives and Conclusion
* Bronchopulmonary Dysplasia Analyst Views
* Bronchopulmonary Dysplasia Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bronchopulmonary-dysplasia-pipeline-analysis-2025-clinical-trials-ema-pdma-fda-approvals-medication-therapies-mechanism-of-action-route-of-administration-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bronchopulmonary Dysplasia Pipeline Analysis 2025: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight here
News-ID: 4114121 • Views: …
More Releases from ABNewswire
Last-Minute Holiday Shoppers Discover Clean Beauty Solutions at Sweetwater Labs
With the holiday countdown accelerating, Sweetwater Labs provides last-minute shoppers with premium natural skincare gifts that arrive in time for celebrations. The brand's seven-year track record and features in publications including Oprah's Gift Issue make it a trusted choice for eleventh-hour gift-giving.
The final days before the holidays have arrived, and shoppers still searching for the perfect gifts are discovering Sweetwater Labs as their solution for premium, meaningful presents. The New…
The Most Important Documents for Immigration (And How to Sign, Notarize, and Sub …
Immigrating to the United States, or anywhere in the world, requires patience, preparation, and a mountain of paperwork. While the immigration process can feel overwhelming, proper document preparation is one of the most important steps you can take to keep your application moving forward. Missing signatures, outdated records, poorly notarized forms, or incorrectly submitted documents are among the most common reasons immigration cases face long delays or outright denial.
How Strong…
Innovative Connections Adds Six New Experts To The Team
FORT COLLINS, Colo. - Dec. 17, 2025 - Innovative Connections [https://innovativeconnectionsinc.com/], a leadership consulting firm dedicated to transforming organizations through connection, purpose, and courageous leadership, has added six new professionals to the team.
The six new consultants, JoAnn Auger, John P. Broschak, Tim Smith, Donna Pearring, JoEllen Wilkins and Debby Neely, bring years of experience from small businesses, Fortune 500s, construction, insurance, financial institutions and engineering.
*
JoAnn Auger: JoAnn brings over 30…
Certificate Authority Market to Reach USD 359.40 Million by 2030 | Driven by Clo …
Mordor Intelligence has published a new report on the Certificate Authority Market, offering a comprehensive analysis of trends, growth drivers, and future projections.
Certificate Authority Market Overview
The certificate authority market [https://www.mordorintelligence.com/industry-reports/certificate-authority-market?utm_source=abnewswire] is poised for significant growth over the next few years, with an estimated market size of USD 208.68 million in 2025 and a forecasted value of USD 359.40 million by 2030, reflecting a CAGR of 11.49%. This growth is primarily…
More Releases for Bronchopulmonary
Bronchopulmonary Dysplasia (BPD) Patient Pool Analysis and Market Forecast 2024- …
Introduction
Bronchopulmonary dysplasia (BPD) is a chronic lung disease that primarily affects premature infants requiring prolonged mechanical ventilation or supplemental oxygen. It remains one of the most serious complications of preterm birth, with lasting effects on pulmonary function, growth, and neurodevelopment.
The condition not only drives neonatal intensive care unit (NICU) costs but also increases long-term healthcare utilization for affected children. Growing global rates of preterm birth, along with improvements in neonatal…
Bronchopulmonary Dysplasia (BPD) Epidemiology Market Analysis
Bronchopulmonary Dysplasia (BPD) represents one of the most significant complications of preterm birth, affecting the respiratory system of premature infants and creating substantial healthcare challenges worldwide. The BPD epidemiology market encompasses therapeutic interventions, diagnostic tools, and supportive care technologies designed to address this chronic lung disease affecting neonates. As medical advances continue to improve survival rates among extremely premature infants, the prevalence of BPD has correspondingly increased, driving demand for…
Bronchopulmonary Dysplasia Treatment Market Growth Projections and Trends (2023- …
Bronchopulmonary Dysplasia (BPD) Treatment Market
Global Bronchopulmonary Dysplasia Treatment Market Overview
The global bronchopulmonary dysplasia (BPD) treatment market is poised for significant growth in the coming years. The market was valued at USD X billion in 2023 and is expected to reach USD Y billion by 2030, expanding at a CAGR of Z% from 2024 to 2030. With advancements in neonatal care and increasing awareness about BPD treatment options, the demand for…
Bronchopulmonary Dysplasia Pipeline Therapeutics Assessment Report 2024 (Updated …
DelveInsight's, "Bronchopulmonary Dysplasia Pipeline Insight 2024" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Bronchopulmonary Dysplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Bronchopulmonary Dysplasia Research. Learn more…
Bronchopulmonary Dysplasia Treatment Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Bronchopulmonary Dysplasia Treatment Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
BDP Market Size And Scope
The global BDP (Butane Diol Propylene) market is witnessing steady growth, fueled by its diverse applications in industries such as…
Bronchopulmonary Dysplasia Market to Reach US$ 445.6 Million by 2034
Market Overview:
The bronchopulmonary dysplasia market reached a value of US$ 269.3 Million in 2023 and expected to reach US$ 445.6 Million by 2034, exhibiting a growth rate (CAGR) of 4.68% during 2024-2034.
The report offers a comprehensive analysis of the bronchopulmonary dysplasia market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market,…
